I was refering to IPO's generally and most IPOs being liquidity...

First 8 Last

Share
Profile

Follow
sidewest

49 Posts.

7

20/09/18

22:25

Post #: 35739002
Share

Originally posted by mike999 ↑

I know the history, I've been involved since day one. The nature of a start up in this industry is that they will not generate revenue short term (and may never if it is not able to be commercialised) however will need to continue to do capital raisings (not ipo's, the initial listing on the asx is the only IPO) to develop the business. This is hugely expensive and will continue for some time. Shareholders should be well aware of this, it is the nature of biotech start ups. I am more than happy with the communication, the board and the potential future. If it proves commercial then the sky is the limit. If not then it will be worth zero.

I agree the current shareprice sucks but there is nothing "disgusting" about it.

Expand

I was refering to IPO's generally and most IPOs being liquidity strategies for seed to cash out of their investments, generally at a premium to what the company is really worth. As can be seen with IBX never getting over IPO price and getting sold into straight away.
In hindsight I should have dumped 1/2 my seed @ 20c with the rest of them and moved on from IBX for a couple of years, but I really like the Tech and wanted to hold full position

I agree that the goal is not to generate revenue but to bring the tech successfuly through trials but was making the point that when the company doesn't have any revenue it would be good to see some restraint in spending at least

IBX Price at posting: 7.4¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply